- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02081807
Sequential Expansion of Comparative Effectiveness of Anticoagulants
2019년 9월 10일 업데이트: Boehringer Ingelheim
Sequential Expansion of Comparative Effectiveness of Oral Anticoagulants: A Cohort Study
This cohort study is the sequential expansion of the comparative effectiveness study of oral anticoagulants and plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and dabigatran) and the occurrence of selected outcomes in patients with non-valvular atrial fibrillation at risk for stroke.
연구 개요
상태
완전한
정황
연구 유형
관찰
등록 (실제)
221228
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02120
- Brigham and Women's Hospital
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
샘플링 방법
비확률 샘플
연구 인구
Patients 18 years of age and older with non-valvular AF initiating oral anticoagulation therapy
설명
Inclusion criteria:
- A recorded diagnosis of atrial fibrillation.
- Initiation of anticoagulant medication (dabigatran (or other new oral anticoagulants as they become available) or warfarin).
- At least 18 years of age on the date of anticoagulant initiation.
- Congestive Heart Failure, Hypertension, Age > 75, Diabetes Mellitus, Prior Stroke or Transient Ischemic Attack, Vascular Disease, Age 65-74, Sex Category (CHA2DS2-VASc) score at least 1
Exclusion criteria:
- Patients with missing or ambiguous age or sex information.
- Patients with evidence of valvular disease.
- Patients with less than 12 months enrolment preceding the date of anticoagulant initiation
- Patients with a dispensing of any oral anticoagulant during the 12 months preceding the date of anticoagulant initiation
- Patients with a nursing home stay during the 12 months preceding the date of anticoagulant initiation
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
다비가트란
|
|
와파린
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Stroke (Hemorrhagic, Ischemic, or Stroke of Uncertain Classification)
기간: From October 2010 to September 2015 (the study period)
|
The rate of overall stroke (hemorrhagic, ischemic or stroke of uncertain classification ) in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: As primary International Classification of Diseases, Ninth Revision (ICD-9) discharge diagnosis (Dx): 431.x
Intracerebral hemorrhage (ICH), 433.x1
Occlusion and stenosis of precerebral arteries with cerebral infarction, 434.x1
Occlusion and stenosis of cerebral arteries with cerebral infarction, 436.x
Acute, but ill-defined cerebrovascular events.
|
From October 2010 to September 2015 (the study period)
|
|
Major Bleeding
기간: From October 2010 to September 2015 (the study period)
|
The rate of major bleeding (Major intracranial bleeding and major extracranial bleed ) in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
For outcome definitions please refer the descriptions section of outcome 8 (major intracranial bleeding) and outcome 9 (major extracranial bleeding).
|
From October 2010 to September 2015 (the study period)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Stroke or Systemic Embolism
기간: From October 2010 to September 2015 (the study period)
|
The rate of stroke (hemorrhagic, ischemic or stroke of uncertain classification ) or systemic embolism in patients matched on propensity scores and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
For outcome definitions please refer the descriptions section of outcome 4 (Systemic embolism), outcome 5 (Ischemic stroke), outcome 6 (Hemorrhagic stroke) and outcome 7 (Stroke uncertain classification).
|
From October 2010 to September 2015 (the study period)
|
|
Systemic Embolism
기간: From October 2010 to September 2015 (the study period)
|
The rate of systemic embolism in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: ICD-9 Diagnoses: 444.x
Arterial embolism.
|
From October 2010 to September 2015 (the study period)
|
|
Ischemic Stroke
기간: From October 2010 to September 2015 (the study period)
|
The rate of ischemic stroke in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: As primary ICD-9 discharge diagnosis (Dx): 433.x1
Occlusion and stenosis of precerebral arteries with cerebral infarction, ICD-9 Dx 434.x1
Occlusion and stenosis of cerebral arteries with cerebral infarction
|
From October 2010 to September 2015 (the study period)
|
|
Hemorrhagic Stroke
기간: From October 2010 to September 2015 (the study period)
|
The rate of hemorrhagic in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: As primary ICD-9 discharge diagnosis (Dx): 431.x
Intracerebral hemorrhage (ICH)
|
From October 2010 to September 2015 (the study period)
|
|
Stroke Uncertain Classification
기간: From October 2010 to September 2015 (the study period)
|
The rate of stroke uncertain classification in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: As primary ICD-9 discharge diagnosis (Dx): ICD-9 Dx code 436.x (acute, but ill-defined cerebrovascular disease).
|
From October 2010 to September 2015 (the study period)
|
|
Major Intracranial Bleeding
기간: From October 2010 to September 2015 (the study period)
|
The rate of major intracranial bleeding in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: ICD-9 diagnosis: 430.x
Subarachnoid hemorrhage (SAH), 431.x
Intracerebral hemorrhage (ICH), 432.x other and unspecified intracranial hemorrhage including 432.1x - subdural hemorrhage
|
From October 2010 to September 2015 (the study period)
|
|
Major Extra-cranial Bleeding
기간: From October 2010 to September 2015 (the study period)
|
The rate of major extracranial bleeding (Major upper GI bleed, major lower and unspecified GI bleed, major urogenital bleed, major other bleed) in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
For outcome definitions please refer the descriptions section of outcome 11 (Major upper gastrointestinal bleeding), outcome 12 (Major lower gastrointestinal bleeding), outcome 13 (Major urogenital bleeding) and outcome 14 (Other major bleeding).
|
From October 2010 to September 2015 (the study period)
|
|
Major Gastrointestinal (GI) Bleeding
기간: From October 2010 to September 2015 (the study period)
|
The rate of major gastrointestinal (GI) bleeding (Major upper GI bleeding, major lower/unspecified GI bleeding) in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
For outcome definitions please refer the descriptions section of outcome 11 (Major upper gastrointestinal bleeding) and outcome 12 (Major lower gastrointestinal bleeding).
|
From October 2010 to September 2015 (the study period)
|
|
Major Upper Gastrointestinal Bleeding
기간: From October 2010 to September 2015 (the study period)
|
The rate of Major upper gastrointestinal bleeding in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: ICD-9 diagnoses: 531.0x, 531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 533.4x, 533.6x, 534.0x, 534.2x, 534.4x, 534.6x, 578.0 OR ICD-9 procedure code 44.43 (endoscopic control of gastric or duodenal bleeding) OR Current Procedural Terminology (CPT) code 43255 (upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate with control of bleeding, any method).
|
From October 2010 to September 2015 (the study period)
|
|
Major Lower Gastrointestinal Bleeding
기간: From October 2010 to September 2015 (the study period)
|
The rate of lower gastrointestinal bleeding in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: Lower GI/unspecified GI site bleeds :Diverticulosis of small intestine with hemorrhage: 562.02,
Diverticulitis of small intestine with hemorrhage: 562.03,
Diverticulosis of colon with hemorrhage: 562.12,
Diverticulitis of colon with hemorrhage: 562.13,
Hemorrhage of rectum and anus: 569.3x,
Angiodysplasia of intestine with hemorrhage: 569.85,
Blood in stool: 578.1x,
Hemorrhage of GI tract, unspecified: 578.9
|
From October 2010 to September 2015 (the study period)
|
|
Major Urogenital Bleeding
기간: From October 2010 to September 2015 (the study period)
|
The rate of major urogenital bleeding in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: ICD-9 diagnoses: Hematuria: ICD-9 Dx: 599.7,
Excessive/frequent menstruation: ICD-9 Dx 626.2x and secondary diagnosis indicating acute bleeding: anemia (280.0,
285.1, 285.9).
Across databases, only one event for dabigatran versus no event among warfarin initiators observed.
Across database, four events for rivaroxaban versus no event among warfarin initiators observed.
Across database, no events for apixaban and warfarin observed.
Therefore HR estimate is not possible.
|
From October 2010 to September 2015 (the study period)
|
|
Other Major Bleeding
기간: From October 2010 to September 2015 (the study period)
|
The rate of Other major bleeding in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: Other major bleeds: Hemathrosis: 719.1x,
Hemopericardium: 423.0x,
Hemoptysis: 786.3x,
Epistaxis: 784.7x,
Hemorrhage not specified 459.0x,
Acute posthemorrhagic anemia 285.1x
|
From October 2010 to September 2015 (the study period)
|
|
Transient Ischemic Attack (TIA)
기간: From October 2010 to September 2015 (the study period)
|
The rate of Transient Ischemic Attack (TIA) in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: ICD-9 Dx code 435.xx (transient cerebral ischemia) as the principal (primary) discharge diagnosis
|
From October 2010 to September 2015 (the study period)
|
|
Myocardial Infarction (MI)
기간: From October 2010 to September 2015 (the study period)
|
The rate of Myocardial infarction (MI) in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: ICD-9 Dx 410.X (acute myocardial infarction) excluding 410.x2 (subsequent episode of care), as the principal (primary) or the next (secondary) diagnosis AND a length of stay (LOS) between 3-180 days, or death if LOS is < 3 days
|
From October 2010 to September 2015 (the study period)
|
|
Venous Thromboembolism (VTE)
기간: From October 2010 to September 2015 (the study period)
|
The rate of Venous Thromboembolism (VTE) in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
For outcome definitions please refer the descriptions section of outcome 18 (Deep vein thrombosis (DVT)) and outcome 19 (Pulmonary Embolism (PE)).
|
From October 2010 to September 2015 (the study period)
|
|
Deep Vein Thrombosis (DVT)
기간: From October 2010 to September 2015 (the study period)
|
The rate of DVT in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: Validated algorithm: ICD-9 451.1x,
ICD-9 451.2x,ICD-9 451.81,
ICD-9 451.9x,
ICD-9 453.1x,
ICD-9 453.2x,
ICD-9 453.8x,
ICD-9 453.9x ; Not in the validated algorithm but will be included following Mini-Sentinel recommendation for VTE outcome: ICD-9 453.40 (Venous embolism and thrombosis of unspecified deep vessels of lower extremity (includes DVT), ICD-9 453.41 (Venous embolism and thrombosis of deep vessels of proximal lower extremity (includes femoral, iliac, popliteal, thigh, and upper leg), ICD-9 453.42 (Venous embolism and thrombosis of deep vessels of distal lower extremity (includes calf, lower leg, peroneal, and tibia), ICD-9 453.0 (Hepatic vein thrombosis)
|
From October 2010 to September 2015 (the study period)
|
|
Pulmonary Embolism (PE)
기간: From October 2010 to September 2015 (the study period)
|
The rate of Pulmonary Embolism (PE) in patients who are matched on propensity score and calendar quarter of initiation.
Event rates were calculated as the total number of patients in each treatment group who had the outcome during follow-up divided by the total person-years at risk in the cohort.
The outcome definition includes following: ICD-9 415.1x (pulmonary embolism and infarction)
|
From October 2010 to September 2015 (the study period)
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
유용한 링크
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2014년 3월 7일
기본 완료 (실제)
2017년 11월 1일
연구 완료 (실제)
2017년 11월 1일
연구 등록 날짜
최초 제출
2014년 3월 6일
QC 기준을 충족하는 최초 제출
2014년 3월 6일
처음 게시됨 (추정)
2014년 3월 7일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2019년 10월 2일
QC 기준을 충족하는 마지막 업데이트 제출
2019년 9월 10일
마지막으로 확인됨
2019년 9월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .